Cargando…
Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil
BACKGROUND: The coronavirus disease (COVID-19) pandemic has had enormous consequences in Brazil and worldwide. Patients with cancer affected by COVID-19 are at a higher risk of developing complications and worse outcomes compared to the non-cancer population, particularly the ones on active systemic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426015/ https://www.ncbi.nlm.nih.gov/pubmed/34567254 http://dx.doi.org/10.3332/ecancer.2021.1269 |
_version_ | 1783749957721784320 |
---|---|
author | Fares, Aline F Fadul, Luiza A Benetton, Barbara Nogueira, Mauricio L Lanza, Marcia Araújo, Daniel V |
author_facet | Fares, Aline F Fadul, Luiza A Benetton, Barbara Nogueira, Mauricio L Lanza, Marcia Araújo, Daniel V |
author_sort | Fares, Aline F |
collection | PubMed |
description | BACKGROUND: The coronavirus disease (COVID-19) pandemic has had enormous consequences in Brazil and worldwide. Patients with cancer affected by COVID-19 are at a higher risk of developing complications and worse outcomes compared to the non-cancer population, particularly the ones on active systemic treatment. Considering the COVID-19’s high transmissibility in asymptomatic and pre-symptomatic patients, we sought to determine the prevalence of COVID-19 infection in patients with solid cancers receiving systemic therapy in a Brazilian public health hospital. Furthermore, we studied whether socio-economic status was associated with prevalence. METHODS: Consecutive asymptomatic patients undergoing treatment for solid tumours at the chemotherapy and infusion centre of Hospital de Base were enrolled. Patients were prospectively tested for severe acute respiratory syndrome coronavirus 2 RNA real-time polymerase chain reaction with nasal and oropharyngeal swabs immediately prior to treatment. A socio-economic survey was carried out prior to testing. Demographic and socio-economic characteristics were summarised in means, medians and proportions. RESULTS: From 6 to 13 October 2020, 148 asymptomatic patients were identified. Of those, 41 were excluded, leaving 107 eligible patients. The mean age of the population was 58 years (SD ± 12.6); 54% were female and 90% were self-identified as White. The most common cancer sites were gastrointestinal tract (36%) and breast (25%). Most patients had a metastatic disease (59%) and were on anticancer treatment involving chemotherapy (95%). Regarding socio-economic status, 46% of our population had either primary school or illiterate as their highest educational level. In terms of monthly income, 92% had a personal income inferior to U$380 and 88% a household income inferior to U$585. Of the 107 patients tested, only 1 (0.9%) was positive for COVID-19. This is a 48-year-old man living in an urban area, with primary school educational level and a monthly personal income inferior to U$390. CONCLUSION: Despite a high prevalence of COVID-19 in Brazil, our cohort demonstrated a low prevalence of COVID-19 (0.9%) amongst asymptomatic patients with cancer. We hypothesise that patients with cancer, independent of their socio-economic status, are aware of the increased risk of developing a severe disease and are adherent to physical distancing, masking and hygiene measures. |
format | Online Article Text |
id | pubmed-8426015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-84260152021-09-24 Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil Fares, Aline F Fadul, Luiza A Benetton, Barbara Nogueira, Mauricio L Lanza, Marcia Araújo, Daniel V Ecancermedicalscience Short Communication BACKGROUND: The coronavirus disease (COVID-19) pandemic has had enormous consequences in Brazil and worldwide. Patients with cancer affected by COVID-19 are at a higher risk of developing complications and worse outcomes compared to the non-cancer population, particularly the ones on active systemic treatment. Considering the COVID-19’s high transmissibility in asymptomatic and pre-symptomatic patients, we sought to determine the prevalence of COVID-19 infection in patients with solid cancers receiving systemic therapy in a Brazilian public health hospital. Furthermore, we studied whether socio-economic status was associated with prevalence. METHODS: Consecutive asymptomatic patients undergoing treatment for solid tumours at the chemotherapy and infusion centre of Hospital de Base were enrolled. Patients were prospectively tested for severe acute respiratory syndrome coronavirus 2 RNA real-time polymerase chain reaction with nasal and oropharyngeal swabs immediately prior to treatment. A socio-economic survey was carried out prior to testing. Demographic and socio-economic characteristics were summarised in means, medians and proportions. RESULTS: From 6 to 13 October 2020, 148 asymptomatic patients were identified. Of those, 41 were excluded, leaving 107 eligible patients. The mean age of the population was 58 years (SD ± 12.6); 54% were female and 90% were self-identified as White. The most common cancer sites were gastrointestinal tract (36%) and breast (25%). Most patients had a metastatic disease (59%) and were on anticancer treatment involving chemotherapy (95%). Regarding socio-economic status, 46% of our population had either primary school or illiterate as their highest educational level. In terms of monthly income, 92% had a personal income inferior to U$380 and 88% a household income inferior to U$585. Of the 107 patients tested, only 1 (0.9%) was positive for COVID-19. This is a 48-year-old man living in an urban area, with primary school educational level and a monthly personal income inferior to U$390. CONCLUSION: Despite a high prevalence of COVID-19 in Brazil, our cohort demonstrated a low prevalence of COVID-19 (0.9%) amongst asymptomatic patients with cancer. We hypothesise that patients with cancer, independent of their socio-economic status, are aware of the increased risk of developing a severe disease and are adherent to physical distancing, masking and hygiene measures. Cancer Intelligence 2021-07-26 /pmc/articles/PMC8426015/ /pubmed/34567254 http://dx.doi.org/10.3332/ecancer.2021.1269 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Fares, Aline F Fadul, Luiza A Benetton, Barbara Nogueira, Mauricio L Lanza, Marcia Araújo, Daniel V Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil |
title | Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil |
title_full | Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil |
title_fullStr | Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil |
title_full_unstemmed | Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil |
title_short | Systematic SARS-CoV-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in Brazil |
title_sort | systematic sars-cov-2-testing for asymptomatic cancer patients treated at a public healthcare tertiary centre in brazil |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426015/ https://www.ncbi.nlm.nih.gov/pubmed/34567254 http://dx.doi.org/10.3332/ecancer.2021.1269 |
work_keys_str_mv | AT faresalinef systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil AT fadulluizaa systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil AT benettonbarbara systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil AT nogueiramauriciol systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil AT lanzamarcia systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil AT araujodanielv systematicsarscov2testingforasymptomaticcancerpatientstreatedatapublichealthcaretertiarycentreinbrazil |